ArticleJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2025

Early and multiple doses of zoledronate mitigates rebound bone loss following withdrawal of receptor activator of nuclear factor kappa-B ligand inhibition.

Albert S Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.